This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/6939950.stm
The article has changed 9 times. There is an RSS feed of changes available.
| Version 3 | Version 4 |
|---|---|
| Alzheimer's drugs remain limited | Alzheimer's drugs remain limited |
| (10 minutes later) | |
| Campaigners have failed in their High Court bid to force the NHS to fund Alzheimer's drugs in people with early-stage disease. | Campaigners have failed in their High Court bid to force the NHS to fund Alzheimer's drugs in people with early-stage disease. |
| However, the National Institute for Health and Clinical Excellence (NICE) has been told to rewrite guidance on how the disease is assessed. | However, the National Institute for Health and Clinical Excellence (NICE) has been told to rewrite guidance on how the disease is assessed. |
| The Court upheld NICE's decision that the drugs are only cost-effective in later-stage disease. | The Court upheld NICE's decision that the drugs are only cost-effective in later-stage disease. |
| It is the first time a judicial review had been sought on NICE guidance. | It is the first time a judicial review had been sought on NICE guidance. |
| Drugs company Eisai brought the case to the High Court with support from fellow drugs firms Pfizer and Shire and the Alzheimer's Society. | Drugs company Eisai brought the case to the High Court with support from fellow drugs firms Pfizer and Shire and the Alzheimer's Society. |
| We are devastated that these drugs will remain unavailable on the NHS to people with early-stage Alzheimer's when they might benefit from them Harriet MillwardAlzheimer's Research Trust NICE: Quick guide | We are devastated that these drugs will remain unavailable on the NHS to people with early-stage Alzheimer's when they might benefit from them Harriet MillwardAlzheimer's Research Trust NICE: Quick guide |
| They were successful on one count - that tests to assess Alzheimer's are discriminatory in people with learning difficulties or those who speak English as a second language. | They were successful on one count - that tests to assess Alzheimer's are discriminatory in people with learning difficulties or those who speak English as a second language. |
| But claims that NICE did not properly evaluate the impact of the drugs on the quality of life of carers and that the figures on the cost of long-term care used in their analysis were too low were not upheld by the court. | But claims that NICE did not properly evaluate the impact of the drugs on the quality of life of carers and that the figures on the cost of long-term care used in their analysis were too low were not upheld by the court. |
| The judge dismissed two further claims of irrationality and procedural fairness. | The judge dismissed two further claims of irrationality and procedural fairness. |
| That means patients with early-stage Alzheimer's will still not be recommended for funding. | That means patients with early-stage Alzheimer's will still not be recommended for funding. |
| Recommendations | Recommendations |
| NICE guidance in 2001 recommended the drugs - which can make it easier to carry out everyday tasks - should be used as standard. | NICE guidance in 2001 recommended the drugs - which can make it easier to carry out everyday tasks - should be used as standard. |
| But guidance published in November 2006, after months of appeals, stated that the drugs should only be prescribed to people with moderate-stage disease. | But guidance published in November 2006, after months of appeals, stated that the drugs should only be prescribed to people with moderate-stage disease. |
| NICE said the drugs, which cost about £2.50 a day, did not make enough of a difference to recommend them for all patients and were not good value for money. | NICE said the drugs, which cost about £2.50 a day, did not make enough of a difference to recommend them for all patients and were not good value for money. |
| HAVE YOUR SAY This is welcome news for all the unsuspecting victims of Alzheimer's in the future David, UK Send us your comments | HAVE YOUR SAY This is welcome news for all the unsuspecting victims of Alzheimer's in the future David, UK Send us your comments |
| Andrew Dillon, chief executive of NICE said: "Our guidance stands and the drugs continue to be recommended only for people with moderate Alzheimer's disease, but the court has asked us to clarify our guidance when it is used for certain groups. | Andrew Dillon, chief executive of NICE said: "Our guidance stands and the drugs continue to be recommended only for people with moderate Alzheimer's disease, but the court has asked us to clarify our guidance when it is used for certain groups. |
| "Alzheimer's disease is a devastating illness, but the evidence indicates that these drugs are simply not effective for some patients. | "Alzheimer's disease is a devastating illness, but the evidence indicates that these drugs are simply not effective for some patients. |
| "That is why we also issued advice last year on the broader support that should be provided for people with Alzheimer's disease and those who care for them, creating core standards for the NHS and care homes that will make a real difference for patients and their families." | "That is why we also issued advice last year on the broader support that should be provided for people with Alzheimer's disease and those who care for them, creating core standards for the NHS and care homes that will make a real difference for patients and their families." |
| Harriet Millward, deputy chief executive of the UK's largest dementia research charity, the Alzheimer's Research Trust, said: "We are devastated that these drugs will remain unavailable on the NHS to people with early-stage Alzheimer's when they might benefit from them. | Harriet Millward, deputy chief executive of the UK's largest dementia research charity, the Alzheimer's Research Trust, said: "We are devastated that these drugs will remain unavailable on the NHS to people with early-stage Alzheimer's when they might benefit from them. |
| "We urgently need to do more research to find better treatments, but research is currently hugely underfunded - we are scraping for every penny to fund vital work." | "We urgently need to do more research to find better treatments, but research is currently hugely underfunded - we are scraping for every penny to fund vital work." |
| But Mervyn Kohler, Help the Aged special adviser said the ruling represented "some progress". | But Mervyn Kohler, Help the Aged special adviser said the ruling represented "some progress". |
| "It is important that NICE examines its guidance on these drugs, not just in the light of the ruling today but bearing in mind the public concern which the case has demonstrated." | "It is important that NICE examines its guidance on these drugs, not just in the light of the ruling today but bearing in mind the public concern which the case has demonstrated." |
| Gordon Lishman, director general of Age Concern, said the ruling was disappointing. | |
| "The drugs can cost as little as £2.50 a day per person and could make day-to-day life far more manageable for thousands of people." |